发布求助
文献互助 智能选刊 最新文献

American journal of hematology/oncology最新文献

筛选
英文 中文
Case Report: Unusual Manifestation of KIT Negative Systemic Mastocytosis. 病例报告:KIT阴性全身性肥大细胞增多症的异常表现。
American journal of hematology/oncology Pub Date : 2016-12-01
Beatriz Cáceres-Nazario, William Cáceres-Perkins, David Tasso, Elizabeth Calderón-Alicea, Daniel Conde-Sterling, Norma Arroyo-Portela
{"title":"Case Report: Unusual Manifestation of <i>KIT</i> Negative Systemic Mastocytosis.","authors":"Beatriz Cáceres-Nazario,&nbsp;William Cáceres-Perkins,&nbsp;David Tasso,&nbsp;Elizabeth Calderón-Alicea,&nbsp;Daniel Conde-Sterling,&nbsp;Norma Arroyo-Portela","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Aggressive systemic mastocytosis is a rare hematologic neoplastic disease that presents with a poor prognosis and low survival rate. It typically manifests with symptoms associated to mast cell release of bioactive substances, causing anaphylaxis, flushing, autonomic and hemodynamic instability, gastric distress and headache. Moreover, more than 95% of cases are related to a mutation in codon 816 of the <i>KIT</i> gene, located on human chromosome 4q12 which codes for a type III receptor tyrosine kinase. We present a 78 year-old Hispanic man diagnosed with the aggressive subtype of systemic mastocytosis, who had an atypical manifestation and a <i>KIT</i> negative variant. The diagnosis was confirmed based on pathologic and serologic findings which included mast cell infiltration of the spleen and bone marrow, malignant ascites and an unusually elevated serum tryptase.</p>","PeriodicalId":89317,"journal":{"name":"American journal of hematology/oncology","volume":"12 12","pages":"24-27"},"PeriodicalIF":0.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573261/pdf/nihms894166.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35360361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PET/CT in the Evaluation of Relapsed or Refractory Hodgkin Lymphoma. PET/CT对复发或难治性霍奇金淋巴瘤的评价。
American journal of hematology/oncology Pub Date : 2016-09-01
Shekeab Jauhari, Sunita D Nasta
{"title":"PET/CT in the Evaluation of Relapsed or Refractory Hodgkin Lymphoma.","authors":"Shekeab Jauhari,&nbsp;Sunita D Nasta","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) has been the most important advance in the assessment of Hodgkin lymphoma (HL) since the introduction of computed tomography (CT). In the frontline management of HL, FDG-PET combined with low-dose CT has emerged as the modality of choice for staging and treatment response assessment. Substantial data have accumulated over the past several years supporting the use of PET/CT in the evaluation and management of relapsed or refractory HL, as well. In this article, we review the role of PET/CT after the frontline treatment of HL, as well as the prognostic utility of PET/CT before autologous and allogeneic stem cell transplantation. We also review the use of PET/CT as a part of response-adapted treatment strategies in relapsed or refractory HL and implications for current and future clinical practice.</p>","PeriodicalId":89317,"journal":{"name":"American journal of hematology/oncology","volume":"12 9","pages":"8-13"},"PeriodicalIF":0.0,"publicationDate":"2016-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810973/pdf/nihms939755.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35836822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data. 补充维生素D对乳腺癌生物标志物的影响:CALGB 70806(联盟)研究设计和基线数据
American journal of hematology/oncology Pub Date : 2016-07-01
Ogheneruona Apoe, Sin-Ho Jung, Heshan Liu, Drew K Seisler, Jayne Charlamb, Patricia Zekan, Lili X Wang, Gary W Unzeitig, Judy Garber, James Marshall, Marie Wood
{"title":"Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data.","authors":"Ogheneruona Apoe,&nbsp;Sin-Ho Jung,&nbsp;Heshan Liu,&nbsp;Drew K Seisler,&nbsp;Jayne Charlamb,&nbsp;Patricia Zekan,&nbsp;Lili X Wang,&nbsp;Gary W Unzeitig,&nbsp;Judy Garber,&nbsp;James Marshall,&nbsp;Marie Wood","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>One in eight women will develop breast cancer over their lifetime with 230,000 women diagnosed in 2015. For this reason, breast cancer prevention efforts are essential. Vitamin D, with anticancer properties, may have a role in prevention of some cancers, including breast cancer. This report discusses the rationale, study protocol, and baseline data for a clinical trial of vitamin D and its effects on breast cancer biomarkers. This study was a randomized controlled trial designed to evaluate the effect of a fixed dose of vitamin D on specfic breast cancer biomarkers. Study participants were randomized to take either vitamin D or placebo for a period of 1 year. All participants had mammograms and blood drawn for serum biomarkers. A subset of participants underwent random periareolar fine needle aspiration to draw tissue for biomarkers. From January 2011 to December 2013, 300 premenopausal women, aged 59 or younger, were recruited from 41 institutions across the United States. A total of 102 women underwent random periareolar fine needle aspiration. The last subject completed the trial in January 2015. Baseline vitamin D levels for all participants ranged from 4-72 ng/mL, with 62% of participants being vitamin D deficient at enrollment (≥30 ng/mL or ≥75 nmo-l/L). The mean body mass index was 27.0 kg/m<sup>2</sup> (range 15.1-53.6 kg/m<sup>2</sup>). 14% and 11.7% of participants were Hispanic or African American, respectively. Accrual and enrollment of participants is feasible for this type of multi-center prevention trial, and it can readily be carried out in a cooperative group setting.</p>","PeriodicalId":89317,"journal":{"name":"American journal of hematology/oncology","volume":"12 7","pages":"4-9"},"PeriodicalIF":0.0,"publicationDate":"2016-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656380/pdf/nihms870350.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35503522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risks of Venous Thromboembolism and Mortality Associated With Erythropoiesis-Stimulating Agents for the Treatment of Cancer-Associated Anemia. 用于治疗癌症相关贫血症的促红细胞生成药物的静脉血栓栓塞风险和死亡率。
American journal of hematology/oncology Pub Date : 2008-08-01
Athena T Samaras, Charles L Bennett
{"title":"Risks of Venous Thromboembolism and Mortality Associated With Erythropoiesis-Stimulating Agents for the Treatment of Cancer-Associated Anemia.","authors":"Athena T Samaras, Charles L Bennett","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":89317,"journal":{"name":"American journal of hematology/oncology","volume":"7 8","pages":"327-332"},"PeriodicalIF":0.0,"publicationDate":"2008-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3156058/pdf/nihms-132667.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30084447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management decisions for nodal metastasis from an unknown primary melanoma. 未知原发黑色素瘤淋巴结转移的治疗决策。
American journal of hematology/oncology Pub Date : 2008-07-01
Chris C Lee, Mark B Faries, Donald L Morton
{"title":"Management decisions for nodal metastasis from an unknown primary melanoma.","authors":"Chris C Lee, Mark B Faries, Donald L Morton","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":89317,"journal":{"name":"American journal of hematology/oncology","volume":"7 7","pages":"306-308"},"PeriodicalIF":0.0,"publicationDate":"2008-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3115657/pdf/nihms71742.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29948261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信